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Abstract 
Brain inflammation is an important factor in the conversion of a healthy brain into an epileptic one, 
a phenomenon known as epileptogenesis, offering a new entry point for prognostic tools. The 
development of anti-epileptogenic therapies to treat before or at disease onset is hampered by our 
inability to predict the severity of the disease outcome. In a rat model of temporal lobe epilepsy we 
aimed to assess whether in vivo non-invasive imaging of brain inflammation at disease onset was 
predictive of spontaneous recurrent seizures (SRS) frequency and severity of depression-like and 
sensorimotor-related comorbidities. To this end, translocator protein, a biomarker of inflammation, 
was imaged by means of positron emission tomography (PET) 2 and 4 weeks post-status epilepticus 
using [
18
F]-PBR111. Translocator protein was highly upregulated 2 weeks post-status epilepticus in 
limbic structures (up to 2.1-fold increase compared to controls in temporal lobe, P < 0.001), 
whereas 4 weeks post-status epilepticus, upregulation decreased (up to 1.6-fold increase compared 
to controls in temporal lobe, P < 0.01) and was only apparent in a subset of these regions. Animals 
were monitored with video-electroencephalography during all stages of disease (acute, latent – first 
seizures appearing around 2 weeks post-status epilepticus - and chronic phases), for a total of 12 
weeks, in order to determine SRS frequency for each subject (range 0.00 – 0.83 SRS/day). We 
found that regional PET uptake at 2 and 4 weeks post-status epilepticus correlated with the severity 
of depression-like and sensorimotor-related comorbidities during chronic epilepsy (P < 0.05 for 
each test). Regional PET imaging did not correlate with SRS frequency, however, by applying a 
multivariate data-driven modeling approach based on translocator protein PET imaging at 2 weeks 
post-status epilepticus, we accurately predicted the frequency of SRS (R = 0.92; R
2
 = 0.86; P < 
0.0001) at the onset of epilepsy. This study not only demonstrates non-invasive imaging of 
translocator protein as a prognostic biomarker to ascertain SRS frequency, but also shows its 
capability to reflect the severity of depression-like and sensorimotor-related comorbidities. Our 
results are an encouraging step towards the development of anti-epileptogenic treatments by 
  
providing early quantitative assessment of SRS frequency and severity of comorbidities with high 
clinical relevance.  
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Abbreviations:  
SRS = spontaneous recurrent seizures 
TSPO = translocator protein 
PET = positron emission tomography 
SE = status epilepticus 
KA = kainic acid 
KASE = kainic acid-induced status epilepticus 
PED = periodic epileptiform discharge 
vEEG = video-electroencephalography 
SUV = standardized uptake value 
PCA = principal component analysis 
PLS = partial least squares 
VOI = volume of interest 
WNT = whisker nuisance task 
SPT = sucrose preference test 
FST = forced swim test 
SO2 = oxygen saturation 
  
1. Introduction 
Epilepsy is one of the most common chronic neurological disorders, with an estimated prevalence 
of nearly 65 million people worldwide (Ngugi et al., 2010). It is characterized by the occurrence of 
spontaneous recurrent seizures (SRS) and a high prevalence of comorbid medical disorders 
resulting in a devastating impact on patient’s daily life (Keezer et al., 2016). Temporal lobe epilepsy  
accounts for approximately 60% of all partial epilepsies, which makes it the most common form of 
focal and often refractory epilepsy that can occur during adulthood (Tellez-Zenteno and Hernandez-
Ronquillo, 2012). Over the last 40 years no progress has been made in preventing new-onset 
epilepsy or stopping the significant rise of cases in the elderly population (Sillanpaa et al., 2016). 
The medicinal therapies available are purely symptomatic, they can have unwanted cognitive or 
neurobehavioral side effects, and they are ineffective in up to 30% of patients with epilepsy (Kwan 
and Brodie, 2000), resulting in poor quality of life (Pugliatti et al., 2007). As a consequence, both 
the prediction and prevention of epilepsy are important public health issues and require urgent 
attention. In this regard, there is a pressing need to develop biomarkers reflecting disease outcome. 
These biomarkers will increase our understanding of epileptogenesis and enable early detection and 
treatment of epilepsy and its comorbidities (Pitkanen et al., 2016). 
Several studies have confirmed increased brain inflammation in animal models during 
epileptogenesis (Amhaoul et al., 2015; Auvin et al., 2010; Brackhan et al., 2016; Dedeurwaerdere et 
al., 2012a; Pernot et al., 2011; Walker et al., 2016). Pitkanen and Engel (2014) defined 
epileptogenesis as “the development and extension of tissue capable of generating spontaneous 
seizures, resulting in a) development of an epileptic condition and/or b) progression of the epilepsy 
after it is established”. Inflammation is recognized to be an important factor in epileptogenesis, 
offering a new target for the development of anti-epileptogenic therapies and prognostic tools 
(Dedeurwaerdere et al., 2012b; Ravizza et al., 2011; Vezzani et al., 2013; Vezzani and Friedman, 
2011). Radiotracers targeting the translocator protein (18 kDa) (TSPO) serve as an in vivo positron 
  
emission tomography (PET) biomarker of inflammation and activated microglia. Recent studies 
indicated that PET imaging of brain inflammation could be used as a tool to investigate drug 
resistance in chronic epilepsy (Bogdanovic et al., 2014; Syvanen et al., 2013). As TSPO has been 
shown to be upregulated in patients with epilepsy (Gershen et al., 2015; Hirvonen et al., 2012; 
Vezzani and Friedman, 2011), as well as in animal models (Amhaoul et al., 2015; Brackhan et al., 
2016; Dedeurwaerdere et al., 2012a), it could represent a valid in vivo biomarker for epilepsy. In 
addition, alterations in its expression have been associated with different psychiatric disorders 
(Rupprecht et al., 2009; Setiawan et al., 2015).  
The development of second-generation tracers targeting TSPO with enhanced pharmacological and 
pharmacokinetic properties (e.g. [
18
F]-PBR111 and [
18
F]-DPA-714), offer an appropriate tool for 
translational in vivo PET imaging. We previously showed the increased uptake of TSPO PET ligand 
[
18
F]-PBR111 in the hippocampus and temporal lobe of kainic acid-induced status epilepticus 
(KASE) rats in the first weeks following status epilepticus (SE) (Amhaoul et al., 2015; 
Dedeurwaerdere et al., 2012a). An increased uptake of the PET ligand [
18
F]-DPA714 has also been 
reported following SE and stroke (Harhausen et al., 2013), with the evaluation of the temporal 
distribution profile using TSPO radioligands showing a peak at 2 weeks post-SE (Amhaoul et al., 
2015; Brackhan et al., 2016). Recently, we have demonstrated a correlation between TSPO 
expression during chronic epilepsy and the occurrence of SRS (Amhaoul et al., 2015). In addition, it 
has been reported that patients with major depressive episodes have increased TSPO levels 
(Setiawan et al., 2015). In summary, there seems to be a link between TSPO during epileptogenesis 
and seizure occurrence, as well as the development of comorbid disorders. However, no 
longitudinal in vivo imaging study evaluating this possible link has yet been performed. 
On this basis we investigated whether in vivo neuroimaging of inflammation by means of [
18
F]-
PBR111 TSPO PET at disease onset (2w post-SE) as well as at established disease (4w post-SE) 
was predictive of epilepsy severity (SRS frequency) and associated depression-like and 
  
sensorimotor-related comorbidities in KASE rats. Animals were scanned at the onset of epilepsy to 
offer a stronger translational significance to this study. For the purpose of our work, we selected the 
KASE rat model of temporal lobe epilepsy, a well-established model characterized by SRS acquired 
after SE (Amhaoul et al., 2015; Drexel et al., 2012; Levesque and Avoli, 2013), behavioral 
abnormalities (Inostroza et al., 2012; Levesque and Avoli, 2013; Mazarati et al., 2008) and poor 
response to antiepileptic drugs (Loscher and Brandt, 2010). This model recapitulates several key 
features of human temporal lobe epilepsy, the most common and refractory form of focal, acquired 
epilepsy in adults (Lothman et al., 1991).  
 
 
 
 
 
 
 
 
 
 
 
 
  
2. Materials and methods 
2.1 Animals 
Five-week-old male Wistar Han rats (Charles River Laboratories, France) were individually housed 
under a 12 h light/dark cycle in a temperature and humidity controlled environment with food and 
water available ad libitum. The animals were acclimatized for 6 days before the start of procedures, 
which were performed according to the European Committee guidelines (decree 86/609/CEE) and 
the Animal Welfare Act (7 USC 2131). All of the experiments were approved by the Ethical 
Committee for Animal Testing (ECD 2014-39) at the University of Antwerp (Belgium). 
 
2.2 Experimental design 
A total of 24 rats were included in the study, of which 18 were induced with kainic acid and six 
were included as control animals. All animals were implanted with MRI-compatible epidural 
electrodes 2 weeks before induction of SE and were monitored continuously (24/7) with video-
electroencephalography (vEEG) during all stages of the disease (acute, latent and chronic epilepsy) 
for the entire study (12 weeks) in order to assess the SRS frequency for each subject. To evaluate 
whether early TSPO expression could predict SRS frequency and comorbidities, the rats were 
scanned at two different points in time during epileptogenesis (14 and 28 days post-SE, disease 
onset and established disease, respectively) (Supplementary Fig. 1) with a non-invasive protocol by 
means of [
18
F]-PBR111 PET imaging, as previously described by our group (Amhaoul et al., 2015; 
Dedeurwaerdere et al., 2012a). Magnetic resonance imaging (MRI) scans were acquired in parallel 
with PET scans to evaluate volumetric changes, as well as for co-registration purposes (Amhaoul et 
al., 2015). Depression-like and sensorimotor-related comorbidities were determined during chronic 
epilepsy using the whisker nuisance task (WNT, 9 and 11 weeks post-SE), the sugar preference test 
(SPT, 12 weeks post-SE) and the forced swim test (FST, 12 weeks post-SE).  
  
 
2.3 Electrode implantation 
The implantation of the electrodes was performed as previously described (Amhaoul et al., 2015) 2 
weeks before the start of the vEEG recordings, allowing an adequate recovery period. A brief 
description of the procedure is provided in the Supplementary data. 
 
2.4 Status epilepticus induction  
Two weeks after electrode implantation, the animals were repeatedly administered low-dose 
injections of kainic acid (KA), as this method has proven its efficacy and has a low mortality rate 
(Dedeurwaerdere et al., 2012a). At SE induction, the rats were aged 7.5 weeks, with an average 
weight of 231 ± 7.39 g. The KASE rats were injected s.c. with an initial dose of 7.5 mg/kg KA 
(A.G. Scientific, USA) and after 1 h, repetitive injections of 2.5 mg/kg were given every half-hour 
unless the animal showed seizure behavior. Injections were repeated until the animals displayed 
convulsive seizures. All animals reached SE (100% induction rate) after receiving an average dose 
of 20.15 ± 1.38 mg/kg of KA and only one rat did not survive the procedure (6% mortality rate). 
During the entire period, the animals were continuously observed and after 4 h of SE, diazepam (4 
mg/kg; NV Roche SA, Belgium) was administered intraperitoneally (i.p.) to reduce seizures. 
Control animals received only saline injections (range of 4–6 injections). At the end of the 
procedure, Hartmann’s solution (10 ml/kg, s.c.) was administered to prevent dehydration. 
Additional care was taken in the days following SE, with the animals receiving enriched soft food 
pellets and Hartmann’s solution (10 ml/kg, s.c.).  
After 4h of observation of SE, the animals were connected to the vEEG system. KASE rats 
displayed electrographic seizures evolving in continuous spiking activity. A decrease in spiking 
frequency and the disappearance of discharges was observed at the time of the transition from 
  
continuous electrographic ictal activity to high-frequency, high-amplitude periodic epileptiform 
discharges (PEDs) with temporary spike activity. We considered the SE terminated only when the 
last PED occurred (Van Nieuwenhuyse et al., 2015). 
 
2.5 vEEG recording and analysis 
A total of 12 weeks of vEEG data were collected from freely moving animals. All control and 
KASE rats were subjected to continuous vEEG for the recording period. The epidural electrode 
assembly was connected to the digital EEG acquisition system (Ponemah P3 Plus; Data Sciences 
International, USA) using a three-channel connector cable with a spring and a rotor-containing 
commutator (Bilaney Consultants, Plastic One Inc., Germany), as previously described (Amhaoul et 
al., 2016). Synchronized video images were recorded with a network video camera (Axis P1343, 
Axis Communications, Sweden), and a night-vision infrared lamp (Raymax 25 IP, Raytec, UK) was 
used to ameliorate video quality during the lights-off period. An experienced investigator constantly 
monitored the animals when they were uncoupled from the vEEG setup for scanning or behavioral 
tests. A total of 10 SRS were documented during these intervals.  
Analysis of vEEG recordings was performed manually using Neuroscore 3.0 (Data Sciences 
International, USA) by an experienced investigator. The identification of SRS was executed as 
previously described (Amhaoul et al., 2016). Briefly, the amplitude of the signal must be at least 
three times the baseline signal (awake), the frequency of the signal must be at least two times the 
baseline signal, and the aberrant EEG-tracing must persist for at least five seconds (Williams et al., 
2009) (Supplementary Fig. 2E and 2F). In addition, to be classified as epileptic activity, video-
recordings were used to visually determine the severity of the SRS according to the modified scale 
of Racine (Amhaoul et al., 2016; Racine, 1972). The duration of SE, the latency to the first SRS, the 
  
duration of SRS, the circadian rhythm of SRS, the temporal evolution of SRS, and the total number 
of SRS (seizure burden) were determined. 
 
2.6 In vivo imaging 
2.6.1 [
18
F]-PBR111 PET imaging 
[
18
F]-PBR111 radiosynthesis was performed on a Fluorsynton I automated synthesis module 
(Comecer Netherlands, the Netherlands) according to Bourdier and colleagues (2012). PET scans 
were performed on an Inveon PET/Computed Tomography (CT) scanner (Siemens Preclinical 
Solution, USA). Physiological monitoring was performed as previously described (Dedeurwaerdere 
et al., 2012a). The rats were anaesthetized using isoflurane (Forene, Belgium) in medical oxygen 
(induction 5%, maintenance 2-2.5%). Respiration rate and body temperature of the animal were 
constantly monitored (Minerve, France) during the entire scanning period and they were in the 
acceptable range during the scan (respiration rate = 60.2 ± 2.1 breaths/min). The core body 
temperature of the animals was maintained at 37 ± 0.5 ºC via a temperature-controlled heating pad. 
The radiotracer (injected dose 8.3 ± 2.7 MBq, specific activity 209.8 ± 21.4 GBq/μmol, cold mass 
0.104 ± 0.017 nmol or 0.35 nmol/kg in a volume of 0.5 ml) was administered into the tail vein over 
a duration of 1 min, using an automated pump (Pump 11 Elite, Harvard Apparatus, USA) and a 
glass syringe (Model 1001 LT SYR, Hamilton Company, USA) (Amhaoul et al., 2015). Brain 
distribution of TSPO ligand [
18
F]-PBR111 was measured by a 15 min static scan 45 min after the 
injection of the radiotracer. After the PET scan, a 10 min 80 kV/500 μA CT scan was performed for 
attenuation correction and for co-registration of the PET images to the MRI data. Iterative PET 
image reconstruction was performed after Fourier rebinning (Defrise et al., 1997) using an ordered-
subset expectation maximization algorithm (OSEM-2D) (Hudson and Larkin, 1994) with 
corrections for dead-time, attenuation and random coincidences provided by the manufacturer.  
  
Standardized uptake values (SUVs) representing the ratio of tissue uptake and injected radioligand 
dose normalized by the body weight of each individual animal were determined. The timing 
window (45-60 min p.i. of [
18
F]-PBR111) for imaging was determined from the time activity curves 
(TACs) from a previous study showing that [
18
F]-PBR111 uptake remains stable during this period 
(Dedeurwaerdere et al., 2012a). Moreover, the reliability of the SUVs was evaluated based on these 
data showing robust correlations between the SUVs and total volume of distribution (Vt) values 
(Supplementary Fig. 3 and Supplementary Table 1). In addition, there was no difference in 
metabolisation of the tracer between controls and KASE rats (controls = 12.66 ± 0.95 % parent 
compound; KASE rats = 13.19 ± 0.56 % parent compound).    
Two PET scans at the 2 weeks post-SE time point were aborted because of a faulty tracer injection 
(KASE 4) or CT failure (KASE 8). These rats were scanned 4 weeks post-SE, but they were 
excluded from the PET analysis. 
2.6.2. T2 MRI 
In the same week as the PET/CT scans, MRI scans were performed as previously described 
(Amhaoul et al., 2015). The animals were anaesthetized using isoflurane (Forene, Belgium) in a 
mixture of N2/O2 (induction 5%, maintenance 2.5%) and placed in prone position into the scanner 
(9.4T Biospec, Bruker, Germany) with the head fixed in a head holder. A rectal thermistor was 
inserted to monitor the body temperature, which was maintained at 37 ± 0.5 ºC by means of a 
feedback-controlled warm air circuitry (MR-compatible Small Animal Heating System, SA 
Instruments, Inc., USA). Blood oxygen saturation (SO2) and respiration rate were monitored 
throughout the experiment using a pulse oximeter and a pressure sensitive sensor under the rat 
(MR-compatible Small Animal Monitoring and Gating System, SA Instruments, Inc., USA) and 
they were in the acceptable range during the scan (SO2 = 97.1 ± 0.8%; respiration rate = 61 ± 1.4 
breaths/min). After a Tripilot scout image, a rapid acquisition with relaxation enhancement (RARE) 
sequence was used to obtain 70 coronal slices with a 0.4 mm thickness (0.17 x 0.114 x 0.35 mm 
  
voxels), an acquisition matrix of 256 x 344, and a field of view (FOV) of 30 x 40 x 28 mm
2
. The 
MR image acquisition procedure lasted for about 10 min, after which the animals were placed in a 
recovery box while heated under an infrared lamp. All data were acquired using ParaVision 5.1 
(Bruker, Germany).  
2.6.3. Data analyses 
Co-registration of PET and MRI was achieved by automated rigid matching of CT to MR images 
using PMOD version 3.3 (PMOD Technologies, Switzerland). Given the sequential acquisition of 
PET and CT on the same bed, the CT to MR rigid transformation was used to overlay the PET and 
MR images. Volumes of interest (VOIs) were manually delineated on the individual MR images for 
each animal in PMOD (PMOD Technologies, Switzerland). The different VOIs included the 
olfactory bulb, the frontal cortex, the hippocampus, the extrahippocampal temporal lobe, the insular 
cortex, the anterior piriform cortex, the thalamus, the hypothalamus, the ventricles and the 
cerebellum. Volumetric assessment of the brain regions investigated was performed by normalizing 
each VOI to the whole brain volume.  
 
2.7 Comorbidities assessment 
All behavioral tasks were performed by researchers blinded to experimental conditions using 
standardized tests (Mazarati et al., 2008; McNamara et al., 2010; Porsolt et al., 1979; Vloeberghs et 
al., 2007) as summarized in Supplementary Fig. 1.  
2.7.1 Whisker nuisance task 
The whisker nuisance task (WNT) measures an animal’s behavioral response to somatosensory 
cortex activation via whisker stimulation to determine altered neuropsychological functions. In 
addition, the scoring of this task takes into consideration anxiety, aggressiveness and the 
  
exploratory behavior of the animals (McNamara et al., 2010). The test was performed 9 and 11 
weeks post-SE in controls (n = 3) and KASE (n = 12) rats. Briefly, the rats were acclimatized in a 
plastic test cage lined with an absorbent pad. The whiskers were manually stimulated with a 
wooden applicator stick for three consecutive 5 min periods, between which the animals were 
observed for 1 min. Behavioral scoring was conducted by 2 blinded observers. High scores (8-16) 
indicate an abnormal response to the stimulation (e.g. rat freezes, becomes agitated or aggressive), 
while low scores (0-4) indicate normal responses (McNamara et al., 2010). At the end of the task, 
the animals were reconnected to the vEEG monitoring system. One animal was excluded from the 
analysis due to experiencing a SRS during the test (KASE 14). 
2.7.2 Sucrose preference test 
A sucrose preference test (SPT) was performed to evaluate anhedonic behavior in KASE rats during 
chronic epilepsy. During the final week of vEEG monitoring (12 weeks post-SE), controls (n = 3) 
and KASE (n = 13) rats were supplied with two identical water bottles, one with 2% sucrose and the 
other without, in the presence of ad libitum food. Every day the position of the bottles was 
exchanged and the consumption from each bottle measured (Vloeberghs et al., 2007). After a 48 h 
period of habituation to avoid bias due to neophobia, the two bottles were again placed in the cage 
and the consumption from each was recorded after a 24 h interval. The preference for sucrose was 
calculated as the relative amount of water with sucrose versus total liquid (water with and without 
sucrose) consumed by the rats. Two animals were excluded from the analysis due to a liquid 
consumption of more than the average of other animals plus 2 standard deviations (2.4-fold and 1.9-
fold higher consumption compared to the average of controls and KASE rats, i.e. 64.5 ± 7.8 ml, 
KASE 2 and KASE 4 respectively).  
2.7.3 Forced swim test 
  
Forced swim test (FST) was performed to determine depressive-like behavior. We employed a 
modified version of the classic FST, in which the animals (controls n = 6; and KASE rats n = 15) 
underwent a single 5 min trial. This modification of the Porsolt protocol (Porsolt et al., 1979) has 
been described as relevant to examining depressive-like behavior (Mazarati et al., 2008). Only a 
single trial test before sacrifice was possible because the exposure of the electrode assembly to 
water may disrupt its functioning. The animals were placed for 5 min in a glass cylinder (65 cm in 
height, 25 cm in width) that was filled with tap water to a height of 50 cm and maintained at 25-
26°C. After each test, the cylinder was washed and refilled with fresh water. Tests were videotaped 
and analyzed blinded to treatment. ‘Time of immobility’ was defined as the time the animal stopped 
swimming and only used minimal movements to keep its head above water. ‘Swimming’ was 
defined as roaming around in the water using synchronized paw movements, and ‘climbing’ as 
upward-directed forceful movements with all paws.  
 
2.8 Data-driven modeling of brain inflammation 
2.8.1. Principal component analysis 
Principal Component Analysis (PCA) is a data reduction method that determines a set of linearly 
uncorrelated components that account for variability in a dataset. In this study, PCA was applied to 
the [
18
F]-PBR111 SUV in the different VOIs of the different animals at 2 and 4 weeks post-SE in 
order to identify different patterns of brain uptake across the animals. A total of 10 dimensions were 
determined and two dimensions were extracted. Factor loadings on each extracted factor were used 
to calculate contributions derived from each VOI. PCA was performed in R (version 3.2.2), using 
the factoextra package. To perform a valid PCA, no guide is given on the number of observations 
needed; however to obtain satisfactory results a subjects-to-variables ratio of 1.2 is required (Barrett 
  
and Kline, 1981). In our study, the subject-to-variable ratio was 2.1, and therefore our sample size 
seemed adequate for the purposes of PCA.   
2.8.2. Partial least squares regression  
Partial least squares (PLS) regression is a method for constructing predictive models when there are 
many highly collinear factors (SUVs for different VOIs). It is based both on a regression of the 
independent variables (factors; VOIs) on the dependent variable (response; SRS/day) and vice versa 
(Naes and Martens, 1985).  
In this study, PLS regression was applied to the [
18
F]-PBR111 uptake of the different VOIs. Only 
KASE rats were included in the analysis since the goal was to predict SRS frequency for each 
subject. A quasi-Poisson distribution was used to account for count data and overdispersion. The 
optimal number of components was obtained by cross validation (Gomez-Carracedo et al., 2007). 
Confidence intervals for the regression coefficients were determined by antithetic bootstrapping 
(Afanador et al., 2013). PLS regression was performed in R (version 3.2.2), using the pls package. 
 
2.9 Statistical analysis 
All analyses were performed by blinded observers. All data were assessed for normality (Shapiro-
Wilk test). No evidence against normality was found, except for the number of SRS. However, 
given the sample size of the control group (n = 6), a Mann-Whitney U test was used to determine 
differences between the control and KASE animals at each time point for all in vivo variables. A 
Wilcoxon signed rank test was used to evaluate the circadian rhythm of SRS. WNT scores were 
compared by two-way repeated-measures ANOVA, while the Mann-Whitney U test was used for 
SPT and FST. A Kruskal-Wallis test with post-hoc Dunn’s multiple comparison test was used to 
compare SRS for the different categories of KASE rats. Spearman’s rank correlation test was used 
to examine the relationship between SRS and all variables in the KASE animals. To investigate 
  
whether a relationship existed between the TSPO PET or MRI data and the behavioral outcomes, as 
well as between the PET SUVs and Vt values, Pearson’s correlation test was used. All of the above-
mentioned analyses were performed with GraphPad Prism (v 6.0) statistical software. The data are 
represented by means ± standard error mean (s.e.m.). All tests were two-tailed and significance was 
set at P < 0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
3. Results 
3.1 Temporal profile of SRS following SE 
The mean duration of SE was 15.07 ± 0.92 h (Supplementary Fig. 2A). The mean latency to the first 
SRS was 22.30 ± 3 days (Supplementary Fig. 2B), while the median was 15.51 days. On average, 
KASE rats experienced 0.32 ± 0.06 SRS per day (in a range of 0.00 – 0.83 SRS/day). All 
electrographic seizures were convulsive (mostly class 4); this was visually confirmed by matching 
the time-locked video recordings. The analysis showed that 2 out of 17 KASE rats (12%) did not 
experience SRS during the whole study. The average duration of SRS was 39.87 ± 0.55 s 
(Supplementary Fig. 2C). In addition, a circadian rhythm was identified: the average number of 
SRS during the lights-on phase was 16.60 ± 4.06 SRS per animal, whereas the seizure burden 
during the lights-off phase was significantly lower, at 3.80 ± 1.30 SRS per animal (P < 0.0001) 
(Supplementary Fig. 2D). The evolution profile of the SRS during the 12 weeks recorded, as well as 
the total number of SRS experienced by each animal (range of 0 – 68 SRS) during the whole 
recording period were also determined (Supplementary Fig. 2G, 2H). 
 
3.2 In vivo imaging of TSPO expression and volumetric changes during epileptogenesis 
In vivo TSPO expression in the brain was determined by means of a longitudinal [
18
F]-PBR111 PET 
scan at 2 and 4 weeks post-SE. The binding of the TSPO ligand [
18
F]-PBR111 2 weeks post-SE was 
significantly increased in KASE rats across the whole limbic system compared to controls (Fig. 
1A): the hippocampus and the temporal lobe (P < 0.0001), the ventricles (P < 0.001), the thalamus 
and the hypothalamus (P < 0.01), and the insular cortex (P < 0.05). High tracer binding was also 
seen in the anterior piriform cortex (P = 0.066), although it was not statistically significant. There 
  
were no significant differences in olfactory bulb, frontal cortex or cerebellum between the control 
and KASE rats. 
The binding of [
18
F]-PBR111 4 weeks post-SE was significantly increased in KASE rats in the 
temporal lobe (P < 0.01), the hippocampus and the thalamus (P < 0.05) compared to controls (Fig. 
1B). There were no significant differences in the remaining regions between the control and KASE 
rats.  
Volumetric assessment of the different brain regions based on MR images showed hippocampal 
volume reduction 2 weeks post-SE (decreased by 16%; P < 0.01) in KASE animals compared to 
controls (Fig. 1C). No significant volumetric changes were found in the remaining VOIs 
investigated.   
MR images 4 weeks post-SE displayed a progressive reduction in hippocampal volume (decreased 
by 22%; P < 0.01), and showed a significant ventricular enlargement (increased by 50%; P < 0.05) 
in KASE animals compared to controls (Fig. 1D). No significant volumetric alterations were found 
in the residual VOIs. 
 
3.3 KASE rats display comorbidities during chronic epilepsy 
Alterations of the somatosensory whisker function were assessed using the WNT at the 9 and 11 
weeks post-SE. KASE rats displayed altered behavior 9 weeks post-SE (controls = 1.81 ± 1.10 
score; KASE rats = 7.42 ± 0.62 score, P = 0.0016) as well as at 11 weeks post-SE (controls = 2.70 ± 
1.26 score; KASE rats = 7.18 ± 0.64 score, P = 0.0103) compared to the controls (Fig. 2A, 2D 
respectively). The inter-rater reliability was consistent both for 9 weeks post-SE (R
2
 = 0.569; P < 
0.0001) and 11 weeks post-SE (R
2
 = 0.645; P < 0.0001). 
  
Anhedonic behavior was assessed using a 24 h sucrose preference test 12 weeks post-SE. It was 
found that the KASE rats had reduced preference for sucrose compared to the control animals 
(controls = 97.51 ± 0.74 %; KASE rats = 91.16 ± 1.55 %, P = 0.004) (Fig. 2G). 
Finally, behavioral despair was assessed using the FST 12 weeks post-SE. KASE rats spent a 
significantly longer time in an immobile state compared to the control animals (P = 0.0267) (Fig. 
2J). Consistent with the increased immobility displayed, KASE rats spent a lower amount of time 
climbing (controls = 118.30 ± 8.72 sec; KASE rats = 75.67 ± 12.77 sec, P = 0.0827), while no 
difference in swimming time was detected (controls = 122.50 ± 12.43 sec; KASE rats = 116.00 ± 
10.09 sec, P = 0.7733). All behavioral scores are summarized in Supplementary Table 2.  
 
3.4 Brain inflammation during epileptogenesis reflects chronic comorbidities 
Behavioral outcomes during chronic epilepsy correlated with [
18
F]-PBR111 uptake at disease onset 
and at established disease, as represented in Fig. 2 and Table 1: comorbid behavior during WNT 9 
and 11 weeks post-SE correlated with higher [
18
F]-PBR111 uptake in the limbic structures shown in 
PET imaging at 2 weeks post-SE (hippocampus: R = 0.87, P < 0.0001, Fig. 2B; and R = 0.76, P < 
0.01, Fig. 2E) and in PET imaging at 4 weeks post-SE (hippocampus: R = 0.67, P < 0.01, Fig. 2C; 
and R = 0.73, P < 0.01 Fig. 2F). In addition, [
18
F]-PBR111 uptake at 2 and 4 weeks post-SE 
correlated with reduced sucrose preference (hippocampus: R = -0.76, P < 0.01, Fig. 2H and R = -
0.81, P < 0.001, Fig. 2I). Furthermore, longer immobility time during FST was observed in subjects 
with higher [
18
F]-PBR111 uptake at 2 and 4 weeks post-SE (hippocampus: R = 0.54, P < 0.05, Fig. 
2K and R = 0.63, P < 0.01, Fig. 2L). No correlation was found between behavioral outcomes and 
SRS or volumetric changes (-0.23 < R < 0.35, P > 0.05 for all pairs of variables). 
 
  
3.5 Data-driven modeling of brain inflammation predicts SRS frequency 
The [
18
F]-PBR111 uptake in any of the individual VOIs did not correlate with SRS frequency for 
any VOI investigated (-0.38 < R < +0.32, P > 0.05 for all pairs of variables). Given the 
multidimensionality of the TSPO PET imaging data, we applied PCA to simplify the representation 
of the variability in the dataset. PCA based on TSPO PET imaging 2 weeks post-SE produced a 
two-dimensional outcome, which accounted for 80% of the variance in the PET data (Dim1 = 
66.6%; Dim2 = 13.4%) (Fig. 3A). The temporal lobe and hippocampus were the most relevant 
regions for explaining PCA variability (Fig. 3B). In addition, we could identify three different 
categories of KASE animals according to PCA and SRS frequency and were accordingly named 
“absent or rare SRS”, “sporadic SRS” and “frequent SRS” (Fig. 3A, 3C). The absent or rare SRS 
(1.50 ± 0.86 SRS) category exhibited a significantly lower number of SRS compared to the frequent 
SRS category (47.25 ± 7.84 SRS) (P < 0.01). No significance difference was found between the 
sporadic SRS (15.30 ± 1.88 SRS) and frequent SRS categories (P = 0.14) or between absent or rare 
SRS and sporadic SRS (P = 0.14).   
PCA based on TSPO PET data 4 weeks post-SE could not determine any difference among subjects 
(Supplementary Fig. 4A).  
In order to construct a predictive model of SRS frequency in KASE animals, we applied PLS 
regression on TSPO PET imaging. PLS regression based on TSPO PET imaging 2 weeks post-SE 
generated a predictive model (R = 0.92; R
2
= 0.86; P < 0.0001) (Fig. 3D). In line with the PCA, a 
model with two components resulted in the best fit (Fig. 3B) and the temporal lobe and 
hippocampus were the most relevant VOIs for explaining the PLS prediction outcome. The PLS 
model was able to predict SRS frequency with high accuracy based on the 2-week PET scan 
acquired before the animals had chronic epilepsy. As a result, PLS regression enabled us to 
determine the SRS frequency for every subject before epilepsy was acquired based on a single non-
invasive TSPO PET scan.  
  
The PLS regression model lost predictive strength when using the TSPO PET data 4 weeks post-SE 
(R = 0.71; R
2 
= 0.44; P < 0.01) (Supplementary Fig. 4C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4. Discussion  
The impact of comorbidities on the quality of life of patients has been underestimated (Keezer et al., 
2016). The development of comorbidities in epilepsy may cause greater impairment in the quality 
of life than seizures (Keezer et al., 2016). Nevertheless, relatively little progress has been made in 
identifying biomarkers and developing new therapies directed specifically at comorbidities (Brooks-
Kayal et al., 2013). We found that regional TSPO PET imaging at disease onset and at established 
disease correlated with depression-like and somatosensory-related comorbidities during chronic 
epilepsy (Fig. 2 and Table 1). The evidence that higher TSPO levels correlate with the severity of 
depressive-like behavior is consistent with the concept that neuroinflammation may contribute to 
sickness behavior. This is supported by previous findings in which patients with mild-to-moderate 
depression had TSPO levels in the brain similar to healthy subjects (Hannestad et al., 2013), 
whereas individuals with severe major depressive episodes had higher TSPO levels in the brain than 
control subjects (Setiawan et al., 2015). Notably, SRS frequency was not a determinant of the extent 
of comorbidities, as previously reported in patients with temporal lobe epilepsy (Gilliam et al., 
2007). While we cannot exclude the possibility that KASE rats had already developed comorbid 
behavior during early phases of the disease, to our knowledge only one study has reported a trend 
for KASE rats to be less mobile during FST in the early stage of the disease (Koh et al., 2007). 
Nevertheless, our finding that regional TSPO PET imaging during epileptogenesis correlates the 
clinical manifestation of comorbidities suggests for the first time a symptomatic biomarker for 
depression-like and sensorimotor-related comorbidities. This finding is clinically relevant and could 
be of value for developing new treatments. 
We have also shown for the first time the capability of a single PET scan, acquired 2 weeks post-SE 
to accurately predict SRS frequency by means of data-driven modeling of brain inflammation at 
onset of epilepsy (Fig. 3A and 3D). To date, the analysis of TSPO PET imaging has been oriented 
towards alterations in separate brain regions, describing increases or decreases in tracer binding 
  
without providing insight into alterations of the brain network during epileptogenesis (Brackhan et 
al., 2016; Dedeurwaerdere et al., 2012a; Harhausen et al., 2013; Toth et al., 2016; Vallez Garcia et 
al., 2015). Taking into account the importance of brain networks in epilepsy, we believe that crucial 
information lies in the 3D region-interdependent changes in the brain. Indeed, differences in 
regional [
18
F]-PBR111 uptake at disease onset and at established disease did not reflect SRS 
frequency, suggesting that single VOIs are not informative enough to explain the development of 
SRS. However, the data-driven modeling of brain inflammation presented here overcomes the 
limitations of a single region analysis and examines PET uptake variations in different regions at 
the same time, thus considering the whole brain network. This method reveals that during 
epileptogenesis brain inflammation is not present in different brain regions independently, and 
interactions between regions appear to be relevant to the prediction of SRS frequency. Hence, by 
shifting away from a categorical analysis of the PET data towards a continuous multi-dimensional 
characterization, more graded aspects of disease ontogenesis were captured. As a result, we were 
able to accurately predict SRS frequency for each subject based on a single non-invasive TSPO 
PET scan at onset of epilepsy. Notably, the most relevant regions that best explain the SRS outcome 
were the temporal lobe and the hippocampus (Fig. 3B), regions well known to be involved in 
seizure generation and spread. Interestingly, the data-driven modeling was able to predict SRS 
frequency based on [
18
F]-PBR111 uptake 2 weeks post-SE (Fig. 3A and 3D), when the first seizures 
were starting to occur (Supplementary Fig. 2B). This time point coincides with the first SRS and 
therefore represents a clinical significant stage to evaluate the disease also in patients. The high 
predictive value of the 2 weeks post-SE time point is because of the elevated level of inflammation 
occurring into the brain, while the loss of predictive strength 4 weeks post-SE is due to the 
resolving of brain inflammation taking place at this time point.  
In this animal model of TLE, we observed depression-like and sensorimotor-related comorbidities 
as well as SRS during chronic epilepsy. The capability of in vivo imaging of brain inflammation to 
  
reflect the severity of the comorbidities and to predict SRS, suggest a link between brain 
inflammation with the investigated comorbidities and SRS. Two key mechanisms associated to 
depression, namely a reduced serotonergic transmission from raphe nucleus into afferent projections 
(such as to the neocortex and hippocampus) and a dysregulation of the hypothalamo-pituitary-
adrenocortical axis, have been reported to be altered in rats following SE (Mazarati et al., 2008; 
Mazarati et al., 2009). Interestingly, epilepsy-related depression can be alleviated when targeting 
brain inflammation, such as by infusion of recombinant interleukin-1 receptor antagonist (Mazarati 
et al., 2010). These findings recommend that depression may, at least in part, result from increased 
brain inflammation, which may explain the direct relationship we found between brain 
inflammation and the severity of the depression-like behavior. On the contrary, epilepsy severity 
(defined by SRS frequency) did not directly correlate with TSPO binding at epilepsy onset. SRS are 
not the result of alterations in a single pathway, but they are the consequence of the composite 
changes of more complex phenomena, which in addition involves interplay between several brain 
areas and their projections. When considering the whole brain network, we could identify a 
relationship between brain inflammation at epilepsy onset and SRS frequency. Several processes 
are involved in the hyperexcitability mediated by inflammation.  The mechanisms underlying the 
proconvulsant effects of released cytokines, such as interleukin-1β and High Mobility Group Box 1, 
include enhanced N-methyl-D-aspartate-mediated inward Ca
2+
 currents (Viviani et al., 2003) and 
increased neuronal synaptic expression of AMPA receptors more permeable to Ca
2+
 mediated by 
TNF-α (Beattie et al., 2002). In addition, TNF-α reduces inhibitory synaptic strength by inducing 
endocytosis of GABAA receptors (Stellwagen et al., 2005). Furthermore, pro-inflammatory 
cytokines can also increase the extracellular glutamate concentration by reducing astrocytic 
glutamate reuptake (Hu et al., 2000). Inflammatory mediators may also trigger transcriptional 
changes, which could promote chronic inflammation and expression of genes involved in 
neurogenesis, cell death, and molecular and synaptic plasticity (O'Neill and Bowie, 2007; Vezzani 
et al., 2011). Finally, inflammatory molecules may contribute to blood-brain barrier breakdown 
  
resulting in parenchymal accumulation of serum albumin, which can induce long lasting 
hyperexcitability by impairing astrocyte ability to buffer potassium and glutamate (Friedman et al., 
2009). Altogether, these molecular changes may contribute to the severity of epilepsy. Although it 
seems that globally epilepsy severity does not correlate with the severity of depression-like 
behavior, it is important to underline that SRS can cause brain inflammation and vice-versa 
(Vezzani et al., 2011), thus seizure-induced inflammation may affect comorbidities during chronic 
epilepsy.  
A major commitment of the field has been the development of disease-modifying treatments to alter 
or even prevent epileptogenesis (Baulac and Pitkanen, 2008; Galanopoulou et al., 2012; Pitkanen et 
al., 2016); nevertheless, no anti-epileptogenic drugs are currently on the market. A primary issue in 
relation to this shortcoming is the selection of subjects to consider for anti-epileptogenic treatment 
during preclinical (and clinical) evaluation trials. Indeed, a lack of biomarkers to predict SRS 
frequency and comorbidities in experimental animal models (as well as in humans) is considered a 
major limiting factor in current anti-epileptogenic studies (Mani et al., 2011; Pitkanen et al., 2016; 
Pitkanen et al., 2013; Schmidt et al., 2014). Choy and colleagues (2014) have shown the potential of 
non-invasive imaging to discriminate seizing animals following febrile status epilepticus. However, 
a biomarker associated with the onset of SRS and comorbidities could be employed in anti-
epileptogenic trials to select animals that will develop similar SRS frequency or severity of 
depression-like and sensorimotor-related comorbidities, reducing variability and hence significantly 
increasing statistical power. Non-invasive neuroimaging of inflammation could thus play a key role 
as biomarker in the selection of animals to include in these preclinical trials, reducing trial costs and 
increasing feasibility.   
A limitation of our study is that we did not perform behavioral tests during the first weeks following 
SE. Since we could not determine when depression-like and sensorimotor-related comorbidities 
appeared, we cannot establish whether TSPO PET imaging is not only reflecting, but also predicting 
  
the severity of depression-like and sensorimotor-related comorbidities. In addition, our study design 
did not allow to determine whether TSPO plays a causative role, future in vivo studies with specific 
TSPO inhibitors or transgenic animals could determine whether TSPO might represent a 
mechanistic biomarker of epilepsy.  
In conclusion, our results not only demonstrate PET imaging of brain inflammation to be a valid 
prognostic biomarker to ascertain SRS frequency, but also to determine the severity of depression-
like and sensorimotor-related comorbidities. Because we scanned the animal at the start of the 
disease onset, our findings have a high clinical relevance.  
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Highlights: 
 KASE rats display depression-like and sensorimotor-related comorbidities. 
 Translocator protein PET imaging correlates severity of depression-like and sensorimotor-
related comorbidities.  
 Translocator protein PET imaging predicts spontaneous seizure frequency. 
 Non-invasive PET imaging is a prognostic biomarker for seizure frequency and reflects 
severity of investigated comorbidities. 
 
  
 
 
 
 
 
 
Figures 
Fig. 1. In vivo imaging during epileptogenesis. (A) [
18
F]-PBR111 uptake 2 weeks post-SE showed 
high levels of TSPO binding in KASE rats (n = 15) compared to control animals (n = 6), not only in 
the limbic regions, but also in the ventricles, thalamus and hypothalamus. (B) [
18
F]-PBR111 uptake 
4 weeks post-SE demonstrated a generalized decrease in tracer uptake in KASE rats (n = 15) 
compared to 2 weeks post-SE. However, at 4 weeks post-SE [
18
F]-PBR111 binding was still higher 
in the thalamus, hippocampus and temporal lobe compared to control animals (n = 6). (C) T2-MRI 2 
weeks post-SE showed hippocampal shrinkage in KASE animals (n = 15) compared to control rats 
(n = 6). (D) T2-MRI 4 weeks post-SE demonstrated a significant decrease in hippocampal volume 
and enlargement of ventricles. Representative coronal PET and MR images are shown in E and F. 
Mann-Whitney U test (A–D). *P < 0.05, **P < 0.01, ***P < 0.001. OB = olfactory bulb, FRONT = 
frontal cortex, INS = insular cortex, PIR = anterior piriform cortex, THAL = thalamus, HYP = 
hypothalamus, HC = hippocampus, TEMP = extrahippocampal temporal lobe, CB = cerebellum, 
WB = whole brain, KASE = kainic acid-induced status epilepticus.  
 
  
Fig. 2. Comorbidities during chronic epilepsy are reflected by [
18
F]-PBR111 uptake during 
epileptogenesis. (A) Whisker nuisance response 9 weeks after SE, KASE animals (n = 11) 
displayed significantly increased behavioral response in comparison with controls (n = 3). [
18
F]-
PBR111 uptake in the hippocampus 2 and 4 weeks post-SE correlated with whisker nuisance scores 
9 weeks post-SE (B-C). Whisker nuisance response 11 weeks after SE, KASE animals (n = 11) 
displayed significantly increased behavioral response in comparison with controls (n = 3) (D). [
18
F]-
PBR111 uptake in the hippocampus 2 and 4 weeks post-SE correlated with whisker nuisance scores 
11 weeks post-SE (E-F). (G) Sucrose consumption 12 weeks post-SE. KASE rats (n = 11) showed 
reduced sucrose consumption compared to control animals (n = 3). Negative significant correlations 
could be determined between [
18
F]-PBR111 uptake in the hippocampus 2 and 4 weeks post-SE and 
sucrose preference 12 weeks post-SE (H-I). (J) Immobility time during FST 12 weeks post-SE. 
KASE rats (n = 15) spent a longer period of time immobile compared to controls (n = 6). The time 
spent immobile during the FST significantly correlated with [
18
F]-PBR111 uptake in hippocampus 
2 and 4 weeks post-SE (K-L). Open circles represent control animals; full circles represent KASE 
rats (B-C, E-F, H-I, and K-L). Two-way repeated measures ANOVA (A, D). Mann-Whitney U test 
(G, J). Pearson correlation (B-C, E-F, H-I, and K-L). *P < 0.05, **P < 0.01. SE = status 
epilepticus, HC = hippocampus, WNT = Whisker nuisance task, SPT = sucrose preference test, FST 
= forced swim test, KASE = kainic acid-induced status epilepticus. Correlations of the other brain 
regions investigated are reported in Table 1.  
 
 
Fig. 3. [
18
F]-PBR111 PET 2 weeks post-SE predicts SRS outcome. (A) Principal component 
analysis (PCA) of [
18
F]-PBR111 2 weeks post-SE (n = 21). PCA represents PET data in a two-
dimensional space accounting for 80% of the total variability of the dataset. (B) Contribution of 
  
each VOI to explaining PCA variability. VOIs above the red line had a major influence; the 
temporal lobe and hippocampus were found to be the most relevant regions in explaining the 
variability in the dataset. (C) Differences in SRS experienced by the three subcategories of KASE 
animals determined based on PCA. Absent or rare SRS (n = 4), sporadic SRS (n = 7) and frequent 
SRS (n = 4). A Kruskal-Wallis test with a post-hoc Dunn’s multiple comparison test. **P < 0.01. 
(D) Partial least squares regression generated a model that can predict SRS frequency for each 
subject (n = 15). The graph reports the number of experienced SRS/day (measured) versus the 
number of predicted SRS/day (estimated) for the model. Spearman’s rank correlation. Each symbol 
represents one animal (A, C and D). SRS = spontaneous recurrent seizures; OB = olfactory bub, 
FRONT = frontal cortex, IC = insular cortex, PIR = anterior piriform cortex, THA = thalamus, HYP 
= hypothalamus, HC = hippocampus, TEMP = extrahippocampal temporal lobe, CB = cerebellum. 
 
 
Table 1. Correlation between [
18
F]-PBR111 PET imaging during epileptogenesis and comorbidities 
during chronic epilepsy (9-12 weeks post-SE). R = Pearson correlation coefficient, R
2
 = Coefficient 
of determination. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistically significant 
correlations are indicated in bold. SE = status epilepticus, VOI = Volume of interest. 
Measure VOI 
[
18
F]-PBR111 PET SUV 2w 
post-SE   
[
18
F]-PBR111 PET SUV 4w 
post-SE 
R P-value R
2
 F   R P-value R
2
 F 
                            
Whisker 
nuisance 
task     
9w post-
SE 
Olfactory 
Bulb 
0.35 0.2108 0.12 1.68   0.47 0.2217 
0.2
2 
3.51 
Frontal 
Cortex 
0.32 0.2583 0.10 1.42 
 
0.49 0.2337 
0.2
4 
3.79 
Insular 
Cortex 
0.67** 0.0079 0.45 
10.0
2  
0.68** 0.0068 
0.4
7 
10.7
8 
Piriform 
Cortex 
0.59* 0.0236 0.35 6.59 
 
0.58* 0.0303 
0.3
4 
6.19 
Ventricles 0.78*** 0.0009 0.61 
18.8
8  
0.79*** 0.0007 
0.6
3 
20.9
0 
Thalamus 0.45 0.1007 0.20 3.18 
 
0.51 0.0614 0.2 4.33 
  
6 
Hypothalamu
s 
0.73** 0.0030 0.53 
13.7
5  
0.75** 0.0020 
0.5
6 
15.8
4 
Hippocampus 0.87**** <0.0001 0.75 
36.9
9  
0.67** 0.0084 
0.5
0 
12.2
3 
Temporal 
Lobe 
0.77** 0.0012 0.59 
17.5
6  
0.77** 0.0025 
0.5
9 
17.5
7 
Cerebellum 0.29 0.3017 0.08 1.13   0.49 0.0744 
0.2
4 
3.92 
                            
Whisker 
nuisance 
task     
11w 
post-SE 
Olfactory 
Bulb 
0.55* 0.0377 0.31 5.45 
 
0.58* 0.0267 
0.3
2 
5.68 
Frontal 
Cortex 
0.38 0.1007 0.33 2.12 
 
0.56* 0.0372 
0.3
1 
4.82 
Insular 
Cortex 
0.62* 0.0158 0.39 7.88 
 
0.63* 0.0152 
0.2
8 
4.81 
Piriform 
Cortex 
0.68** 0.0069 0.46 
10.5
9 
 
0.59* 0.0247 
0.3
2 
5.72 
Ventricles 0.79*** 0.0007 0.63 
20.6
7 
 
0.77** 0.0013 
0.5
9 
17.5
3 
Thalamus 0.61* 0.0203 0.37 7.14 
 
0.62* 0.0176 
0.3
8 
7.57 
Hypothalamu
s 
0.77** 0.0011 0.60 
18.2
6 
 
0.72** 0.0029 
0.5
2 
13.4
7 
Hippocampus 0.76** 0.0013 0.60 
18.6
6 
 
0.73** 0.0025 
0.5
7 
16.1
5 
Temporal 
Lobe 
0.61* 0.0261 0.37 6.59 
 
0.59* 0.0324 
0.3
5 
5.98 
Cerebellum 0.30 0.2365 0.09 1.24   0.53* 0.0492 
0.2
8 
3.74 
                            
Sucrose 
preferen
ce test 
12w 
post-SE 
Olfactory 
Bulb 
-0.21 0.4716 0.04 0.55 
 
-0.58* 0.0286 
0.4
2 
7.29 
Frontal 
Cortex 
-0.23 0.4470 0.05 0.62 
 
-0.57 0.0530 
0.3
3 
4.95 
Insular 
Cortex 
-0.60* 0.0294 0.36 6.26 
 
-0.69* 0.0149 
0.4
8 
9.46 
Piriform 
Cortex 
-0.52 0.0664 0.27 4.15 
 
-0.63* 0.0404 
0.3
9 
6.66 
Ventricles -0.60* 0.0278 0.36 6.41 
 
-0.63* 0.0159 
0.4
0 
7.33 
Thalamus -0.43 0.1394 0.18 2.53 
 
-0.49 0.0709 
0.2
4 
3.60 
Hypothalamu
s 
-0.41 0.1586 0.17 2.28 
 
-0.60* 0.0206 
0.4
8 
9.37 
Hippocampus -0.76** 0.0013 0.58 
15.4
7  
-0.81*** 0.0004 
0.6
9 
22.7
6 
Temporal 
Lobe 
-0.80*** 0.0010 0.64 
19.9
5  
-0.84*** 0.0008 
0.7
1 
25.1
8 
Cerebellum -0.13 0.6539 0.01 0.21   -0.46 0.1675 
0.2
1 
2.68 
                           
Forced 
swim 
test 12w 
post-SE 
Olfactory 
Bulb 
-0.14 0.5205 
0.02
5 
0.42 
 
0.47* 0.0287 
0.2
2 
5.06 
Frontal 
Cortex 
-0.19 0.3910 
0.03
8 
0.77 
 
0.52* 0.0155 
0.2
7 
7.07 
Insular 
Cortex 
0.42 0.0524 0.18 4.28 
 
0.68*** 0.0005 
0.4
7 
17.2
5 
Piriform 
Cortex 
0.22 0.3375 0.05 0.96 
 
0.65** 0.0014 
0.4
2 
13.9
6 
Ventricles 0.56** 0.0072 0.32 9.06 
 
0.63** 0.0020 
0.4
0 
12.7
4 
Thalamus 0.25 0.2618 0.06 1.33 
 
0.61** 0.0030 0.3 11.5
  
7 6 
Hypothalamu
s 
0.31 0.1644 0.09 2.09 
 
0.28 0.2084 
0.0
8 
1.96 
Hippocampus 0.54* 0.0110 0.29 7.94 
 
0.63** 0.0019 
0.4
0 
12.9
8 
Temporal 
Lobe 
0.66** 0.0011 0.43 
14.8
6  
0.69*** 0.0005 
0.4
7 
17.4
5 
Cerebellum 0.22 0.3278 0.05 1.01   0.55** 0.0084 
0.3
1 
8.63 
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